Colistin is used systemically in critically ill patients for treatment of infections caused by multi-drug resistant (MDR) Gram-negative bacteria, e.g., Acinetobacter baumanii. It is potentially nephro- and neurotoxic. It is recommended to decrease the dose of colistin in case of renal impairment or renal replacement therapies (RRT) but clear recommendations are not available yet. The aim of this retrospective study was to determine colistin use patterns in critically ill patients in Pauls Stradiņš University Hospital. Forty patients were included in this study. The most common indications for colistin were pneumonia associated with mechanical ventilation or sepsis caused by MDR A. baumanii. Median duration of colistin therapy was 11.5 (IQR 7.0; 17.0) days and median cumulative dose was 91.5 (43.0; 150.0) million units (MU). The usual regimen was 9 MU as loading dose and 3 MU three times daily as maintenance dose, but in case of renal impairment and RRT colistin regimens varied a lot between the patients. In 21% (7 from 33) of cases, acute kidney injury (AKI) was observed during colistin therapy (serum creatinine increases more than twice from baseline). All these AKI cases occurred in patients with previously normal renal function and none of the patients in this group needed RRT.
If the inline PDF is not rendering correctly, you can download the PDF file here.
Akajagbor D. S. Wilson S. L. Shere-Wolfe K. D. Dakum P. Charurat M. E. Gilliam B. L. (2013). Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin b in critically ill patients at a tertiary care medical center. Clin. Infect. Dis. 57 (9) 1300–1303.
Anonymous (2015). European Medicines Agency completes review of polymyxin-based medicines. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Polymyxin_31/WC500176333.pdf
Anonymous (2016). Consensus Guidance on High Dose Colistimethate Sodium (Colistin) in Management of Carbapenemase produsing enterobacteriaceae (CPE) in Adults. Available from: https://www.scottishmedicines.org.uk/files/sapg/SAPG_High_Dose_Colistin_Treatment_in_Adults_Consensus_Guidance.pdf
Balkan I. I. Dogan M. Durdu B. Batirel A. Hakyemez I. N. Cetin B. Karabay O. Gonen I. Ozkan A. S. Uzun S. Demirkol M. E. Akbas S. Kacmaz A. B. Aras S. Mert A.Tabak F. (2014). Colistin nephrotoxicity increases with age. Scand. J. Infect. Dis. 46 678–685.
Dalfino L. Puntillo F. Mosca A. Monno R. Spada M. L. Coppolecchia S. Miragliotta G. Bruno F. Brienza N. (2012). High-dose extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clinical Infectious Diseases?: An Official Publication of the Infectious Diseases Society of America. Clin. Infect. Dis. 54 (12) 1720–1726.
Dhariwal A. K. Tullu M. S. (2013). Colistin: Re-emergence of the “forgotten” antimicrobial agent. J. Postgr. Med. 59 208–215.
Garonzik S. M. Li J. Thamlikitkul V. Paterson D. L. Shoham S. Jacob J. Silveira F. P. Forrest A. Nation R. L. (2011). Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55 (7) 3284–3294.
Gauthier T. P. Wolowich W. R. Reddy A. Cano E. Abbo L. Smith L. B. (2012). Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob. Agents Chemother. 56 (5) 2392–2396.
Honore P. M. Jacobs R. Joannes-Boyau O. Boer W. De Waele E. Van Gorp V. Spapen H. D. (2013). Continuous renal replacement therapy allows higher colistin dosing without increasing toxicity. J. Transl. Intern. Med. 1 (1) 6–8.
Javan O. Shokouhi S. Sahraei Z. (2015). A review on colistin nephrotoxicity. Eur. J. Clin. Pharmacol. 71 (7) 801–810.
Kassamali Z. Rotschafer J. C. Jones R. N. Prince R. A. Danziger L. H. (2013). Polymyxins: Wisdom does not always come with age. Clin. Infect. Dis. 57 (6) 877-883.
Nation R. L. Garonzik S. M. Li J. Thamlikitkul V. Giamarellos-Bourboulis E. J. Paterson D. L. Turnidge J. D. Forrest A. Silveira F. P. (2016). Updated US and European dose recommendations for intravenous colistin: How do they perform? Clin. Infect. Dis. 62 (5) 552–558.
Omrani A. S. Alfahad W. A. Shoukri M. M. Baadani A. M. Aldalbahi S. Almitwazi A. A. Albarrak A. M. (2015). High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann. Clin. Microbiol. Antimicrob. 14 (3) 1–6.
Ortwine J. K. Sutton J. D. Kaye K. S. Pogue J. M. (2015). Strategies for the safe use of colistin. Expert Rev. Anti. Infect. Ther. 13 (10) 1237–1247.
Plachouras D. Karvanen M. Friberg L. E. Papadomichelakis E. Antoniadou A. Tsangaris I. Karaiskos I. Poulakou G. Kontopidou F. Armaganidis A. Cars O. Giamarellou H. (2009). Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother. 53 (8) 3430–3436.
Rocco M. Montini L. Alessandri E. Venditti M. Laderchi A. De Pascale G. Raponi G. Vitale M. Pietropaoli P. Antonelli M. (2013). Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: A retrospective cohort study. Crit. Care17 (4) R174.
Santamaría C. Mykietiuk A. Temporiti E. Stryjewski M. E. Herrera F. Bonvehi P. (2009). Nephrotoxicity associated with the use of intravenous colistin. Scand. J. Infect. Dis. 41 (10) 767–769.